

1653



Please type a plus sign (+) inside this box → ☐ +

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB No. 1-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RECEIVED
OCT 1 2001
FBI CENTER 1600/2900

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/908,955	
	Filing Date	July 19, 2001	
	First Named Inventor	SAKSENA, et al	
	Group Art Unit	To Be Assigned	
	Examiner Name	To Be Assigned	
Total Number of Pages in This Submission	12	Attorney Docket Number	IN01159K

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) <div>Return Post Card</div>
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	SCHERING-PLOUGH CORPORATION PATENT DEPARTMENT, K-6-1-1990 PALAIYUR S. KALYANARAMAN, REG. NO. 34634
Signature	
Date	September 24, 2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: Sept. 24, 2001			
Typed or printed name	PALAIYUR S. KALYANARAMAN		
Signature		Date	Sept. 24, 2001

+ Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PATENT CASE IN01159K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2/a
10-11-01

TECH CENTER 16082930

OCT 01 2001

RECEIVED

In re Application of:

Saksena et al.

Serial No.: 09/908,955

Filing Date: July 19, 2001

For Patent For:

:
: Examiner: To be assigned
: Group Art Unit: To be assigned

Novel Peptides as NS3-Serine Protease Inhibitors of Hepatitis C Virus

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231


Sir:

PRELIMINARY AMENDMENT


Please add the following new claims in the present application:

NEW CLAIMS:

Claim 50 (New Claim): The compound of claim 8, wherein R³ is:



Claim 51 (New Claim): A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers, tautomers, racemates and prodrug of said compound, and pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound being the compound of structure shown below:



Claim 52 (New Claim): A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers, tautomers,